Palisade Bio, Inc.
General ticker "PALI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $8.0M (TTM average)
Palisade Bio, Inc. follows the US Stock Market performance with the rate: 45.1%.
Estimated limits based on current volatility of 4.2%: low 2.20$, high 2.40$
Factors to consider:
- Total employees count: 9 (-25.0%) as of 2023
- Top business risk factors: Substantial doubt about continuing as a going concern, Operational and conduct risks, Dependence on single product candidate, Regulatory and compliance, Third-party risks
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.03$, 3.73$]
- 2026-12-31 to 2027-12-31 estimated range: [0.58$, 2.25$]
Financial Metrics affecting the PALI estimates:
- Positive: with PPE of -1.4 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -9.33 <= 0.07
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 0 > -0.65
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 96.31 > 64.25
- Positive: Inventory ratio change, % of 0 <= 0
Short-term PALI quotes
Long-term PALI plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.25MM | $0.00MM | $0.00MM |
| Operating Expenses | $13.32MM | $14.86MM | $18.06MM |
| Operating Income | $-13.07MM | $-14.86MM | $-18.06MM |
| Non-Operating Income | $0.77MM | $0.42MM | $1.27MM |
| Interest Expense | $0.01MM | $0.01MM | $0.01MM |
| R&D Expense | $6.89MM | $9.06MM | $10.19MM |
| Income(Loss) | $-12.30MM | $-14.44MM | $-16.78MM |
| Profit(Loss)* | $-12.30MM | $-14.44MM | $-16.78MM |
| Stockholders Equity | $11.31MM | $7.49MM | $129.38MM |
| Assets | $14.05MM | $10.88MM | $134.34MM |
| Operating Cash Flow | $-11.13MM | $-12.19MM | $-10.85MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-0.00MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $11.19MM | $9.58MM | $134.44MM |
| Earnings Per Share** | $-26.97 | $-10.20 | $-0.30 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.